One-Year Effectiveness Study of Intravitreous Ranibizumab in Wet (Neovascular) Age-Related Macular Degeneration: A Meta-Analysis.
Michael Y GuoMahyar EtminanJasmine Z ChengZafar ZafariDavid A L MaberleyPublished in: Pharmacotherapy (2018)
This meta-analysis suggests visual improvements at 12 months of 0.5-mg ranibizumab use in patients with wAMD. A higher gain in VA was observed when pooling results from RCTs compared to those in observational studies.